Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents
SB Kaushik, MG Lebwohl - Journal of the American Academy of …, 2019 - Elsevier
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular
diseases. These factors have a significant impact on the decision to use one therapy over
another. The past decade has seen a paradigm shift in our understanding of the
pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several
new drugs have gained approval by the US Food and Drug Administration, expanding the …
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular
diseases. These factors have a significant impact on the decision to use one therapy over
another. The past decade has seen a paradigm shift in our understanding of the
pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several
new drugs have gained approval by the US Food and Drug Administration, expanding the …
